Fluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics. by Hsu, Yuan-Hao et al.
UC San Diego
UC San Diego Previously Published Works
Title
Fluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket 
association defined by hydrogen/deuterium exchange and molecular dynamics.
Permalink
https://escholarship.org/uc/item/3c7873d9
Journal
Journal of the American Chemical Society, 135(4)
ISSN
0002-7863
Authors
Hsu, Yuan-Hao
Bucher, Denis
Cao, Jian
et al.
Publication Date
2013-01-16
DOI
10.1021/ja306490g
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Fluoroketone Inhibition of Ca2+-Independent Phospholipase A2
through Binding Pocket Association Defined by Hydrogen/
Deuterium Exchange and Molecular Dynamics
Yuan-Hao Hsu,*,†,‡,⊥,▲ Denis Bucher,‡,▲ Jian Cao,†,‡ Sheng Li,§ Sheng-Wei Yang,⊥ George Kokotos,▽
Virgil L. Woods, Jr,§ J. Andrew McCammon,†,‡,∥ and Edward A. Dennis*,†,‡
†Department of Pharmacology, ‡Department of Chemistry and Biochemistry, §Department of Medicine, and ∥Howard Hughes
Medical Institute, University of California, San Diego, La Jolla, California 92093-0601, United States
⊥Department of Chemistry, Tunghai University, Taichung, Taiwan
▽University of Athens, Panepistimiopolis, Athens 15771, Greece
ABSTRACT: The mechanism of inhibition of group VIA
Ca2+-independent phospholipase A2 (iPLA2) by fluoroketone
(FK) ligands is examined by a combination of deuterium
exchange mass spectrometry (DXMS) and molecular dynam-
ics (MD). Models for iPLA2 were built by homology with the
known structure of patatin and equilibrated by extensive MD
simulations. Empty pockets were identified during the
simulations and studied for their ability to accommodate FK
inhibitors. Ligand docking techniques showed that the potent
inhibitor 1,1,1,3-tetrafluoro-7-phenylheptan-2-one (PHFK) forms favorable interactions inside an active-site pocket, where it
blocks the entrance of phospholipid substrates. The polar fluoroketone headgroup is stabilized by hydrogen bonds with residues
Gly486, Gly487, and Ser519. The nonpolar aliphatic chain and aromatic group are stabilized by hydrophobic contacts with
Met544, Val548, Phe549, Leu560, and Ala640. The binding mode is supported by DXMS experiments showing an important
decrease of deuteration in the contact regions in the presence of the inhibitor. The discovery of the precise binding mode of FK
ligands to the iPLA2 should greatly improve our ability to design new inhibitors with higher potency and selectivity.
■ INTRODUCTION
Group VI phospholipase A2 (GVI PLA2), also known as Ca
2+-
independent phospholipase A2 (iPLA2), constitutes one group
of the superfamily of phospholipase A2 enzymes that hydrolyzes
the sn-2 ester bond of phospholipids to release free fatty
acids.1,2 These fatty acids can be metabolized into pro-
inflammatory eicosanoids, including prostaglandins and leuko-
trienes.3
Ca2+-independent phospholipases were so named after the
discovery that their activity is not increased in the presence of
Ca2+, in contrast to the other then-known PLA2s. The first
discovered and best-studied iPLA2 is the 85-kDa GVIA iPLA2
(also known as iPLA2β).
4 Different variants of iPLA2s were later
discovered, leading to their classification into various
subgroups. To date, six subgroups have been identified,
including GVIA (iPLA2β; PNPLA9),
5−8 GVIB (iPLA2γ;
PNPLA8),9,10 GVIC (iPLA2δ; PNPLA6),
11 GVID (iPLA2ε;
PNPLA3),12 GVIE (iPLA2ξ; PNPLA2),
13−15 and GVIF PLA2
(iPLA2η; PNPLA4).
2,16−18 These GVI iPLA2s all contain a
serine active site in a patatin-like catalytic domain. GVIA iPLA2
has been reported to be activated by oligomerization, ATP
binding, caspase cleavage, and membrane interaction1 and to
localize in mitochondria in various types of cells.19−21
The important roles of iPLA2 in regulation of the
inflammatory response and in mitochondrial maintenance
suggest that it could be implicated in a large number of genetic
and age-related diseases. GVIA iPLA2 has been suggested to be
responsible for the deacylation of cardiolipin and mono-
lysocardiolipin accumulation in Barth syndrome and hyper-
tensive heart failure.22,23 Clinical studies have demonstrated
that mutations of GVIA iPLA2 are associated with “neuro-
degeneration with brain iron accumulation” (NBIA) disorders
and infantile neuroaxonal dystrophy.24−27 Recently, it was
demonstrated that GVIA iPLA2 plays a key role in the onset
and progression of experimental autoimmune encephalomye-
litis (EAE) indicating that this enzyme may be a target for the
development of novel therapies for multiple sclerosis.28 Recent
cellular studies have also suggested that iPLA2 may interfere
with the protein p53 pathway. In particular, inhibition of iPLA2
was shown to decrease prostate cancer cell growth, suggesting
iPLA2 could be a new anticancer target.
29,30
Due to the considerable pharmaceutical interest in iPLA2, a
current challenge is the design of a safe inhibitor that is also
highly selective for this class. Several ligands have already been
shown to inhibit the phospholipase, lysophospholipase, and
transacylase activities of GVIA iPLA2.
31−34 The most
commonly used iPLA2 inhibitor is bromoenol lactone (BEL),
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and the S enantiomer (S-BEL), has been shown to
preferentially inhibit iPLA2.
33−37 Although BEL inhibits iPLA2
through acylation of a critical cysteine,38 it is also highly toxic,
as it reacts with cysteines in other proteins. Methyl arachidonyl
fluorophosphonates, known as MAFP, are potent inhibitors of
iPLA2
31 but their action is irreversible, which typically translates
into increased toxicity in vivo. In addition, 2-oxoamides have
been shown to inhibit GVIA iPLA2 but are also active against
GIVA cPLA2.
39 Finally, fatty acyl trifluoromethyl ketones,
including arachidonyl and palmitoyl trifluoromethyl ketones,
have been identified as promising inhibitors of GVIA iPLA2.
33
Fluoroketone (FK) inhibitors were designed to target serine
active sites and consequently are also active against cPLA2.
However, FK inhibitors were shown to become selective for
iPLA2 versus cPLA2 and sPLA2, after a modification of the
fluoroketone group, and the addition of a hydrophobic
terminus connected by a medium-length carbon chain to
mimic the fatty acid chain.40 One pentafluoroketone, FKGK11,
has been shown to be a potent and selective GVIA iPLA2
inhibitor demonstrating in vivo activity against EAE.27 Another
FK ligand, 1,1,1,3-tetrafluoro-7-phenylheptan-2-one (PHFK),40
contains a phenyl ring, a five-carbon linker, and an additional
fluorine on the carbon adjacent to the ketone of the
trifluoromethylketone. It shows great promise as a lead
compound for iPLA2-associated diseases; hence, we have
focused in this paper on resolving its binding mode.
Previous computational studies on the inhibition of PLA2
have mainly focused on group IVA (GIVA, cPLA2)
proteins,41,42 where high-resolution structural data exist. The
task of determining the binding mode of FK inhibitors for
GVIA PLA2 is complicated by the lack of high-resolution X-ray
structures. GVI iPLA2 enzymes are known to be composed of
an N-terminal regulatory domain containing seven ankyrin
repeats and a C-terminal catalytic domain containing the active-
site dyad (Ser519/Asp652) (Figure 1A). The catalytic domain
has low sequence homology to other lipases, such as cPLA2,
and is distinct from the highly disulfide-bonded sPLA2s.
Previously, we proposed a rudimentary model of the catalytic
domain based on the structure of the patatin protein,43 a lipid
acyl hydrolase found in potato with sequence similarity with the
catalytic domain of iPLA2. The model could explain why some
regions of the catalytic domain appeared particularly accessible
to the solvent in deuterium exchange mass spectrometry
(DXMS) experiments.43 However, the binding of inhibitors and
the stability of the model in molecular dynamics (MD)
simulations were not studied.
In this paper, computational methods are coupled with
experimental DXMS techniques to study the atomic-level
details of the iPLA2−PHFK complex. A new model for the
catalytic domain of iPLA2 is proposed and shown to be stable
by extensive MD simulations under aqueous conditions. Ligand
docking techniques were able to uncover a favorable binding
mode for FK inhibitors, and H/D exchange experiments
provide experimental information about the effect of PHFK
binding on solvent accessibility, giving strong support to the
proposed binding mode. The details of protein−inhibitor
interactions are discussed, as well as implications for the
catalytic mechanism.
■ MATERIALS AND METHODS
Materials. 1-Palmitoyl-2-arachidonoyl-sn-phosphatidylcholine
(PAPC) was obtained from Avanti Polar Lipids, and D2O (99.96%)
was obtained from Cambridge Isotope Laboratories. The PHFK ligand
was synthesized as previously described.40 All other reagents were
analytical reagent grade or better.
Protein Expression, Purification, and Activity Assay. GVIA
iPLA2 containing an N-terminal His6-tagged insertion at the third
residue was expressed by use of recombinant baculovirus in suspension
cultures of Sf9 insect cells.43 For the specific activity of iPLA2, assays
(Figure 3) were performed in buffer composed of 100 mM N-(2-
hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES) at pH 7.5, 2
mM ATP, and 5 mM dithiothreitol (DTT). The mixed micelles were
composed of 0.1 mM PAPC (80 000 cpm) and 0.4 mM Triton X-100
in a final volume of 500 μL. The reaction was initiated by adding 0.2
μg of iPLA2 to mixed micelles and incubated at 40 °C for 30 min. After
incubation, the reaction was quenched, and the fatty acids were
extracted by a modified Dole protocol as previously described.40
Preparation of Deuterated Samples. Before the DXMS
experiments were carried out, 5 mM PHFK inhibitor (100× stock in
100% dimethyl sulfoxide, DMSO) was added to iPLA2 to a final 50
μM PHFK in 1% DMSO and incubated at 23 °C for 10 min. Control
experiments contain 1% DMSO. Hydrogen/deuterium exchange
experiments were initiated by mixing 40 μL of iPLA2 (containing 50
μg of iPLA2) in protein buffer with 80 μL of D2O buffer to a final
concentration of 63.3% D2O at pH 7.0. D2O buffer was prepared by
mixing 99.99% D2O with 20× buffer solution in H2O and generated
95% D2O buffer. Final D2O buffer contained 50 mM 3-(N-
morpholino)propanesulfonic acid (MOPS) (pH 6.9), 100 mM
NaCl, 2 mM DTT, and 2 mM ATP.
The samples were incubated at 23 °C for an additional 10, 30, 100,
300, 1000, or 3000 s. The deuterium exchange was quenched by
adding 80 μL of ice-cold quench solution (2.5% formic acid, 2.5 M
guanidine hydrochloride) that acidified the sample to a final pH = 2.5.
The samples were then immediately frozen on dry ice. Back exchange
levels were calculated as previously reported.43,44 Vials with frozen
samples were stored at −80 °C until analysis, usually within 3 days.
Proteolysis−Liquid Chromatography−Mass Spectrometry
Analysis of Samples. All steps were performed at 0 °C as previously
described.43−45 The quenched sample was digested by porcine pepsin-
immobilized column and the proteolyzed peptides were separated on a
C18 column.The peptides were analyzed on an LCQ Classic (Thermo
Finnigan, Inc.) electrospray ion trap-type mass spectrometer and an
Figure 1. (A) Schematic representation of GVIA iPLA2 sequence
information with the location of the active-site dyad, Ser519/Asp652.
(B) Initial guess for the structure of the catalytic domain based on
patatin. (C) Equilibrated structure after extensive (∼200 ns) MD
simulation. (D) Superposition between initial guessed structure and
equilibrated structure, showing a high degree of consistency.
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electrospray Q-TOF (time-of-flight) mass spectrometer (Micromass).
Peptides were identified by tandem mass spectrometry (MS/MS) data
through SEQUEST (Thermo Finnigan, Inc.). DXMS Explorer (Sierra
Analytics Inc., Modesto CA) was used to analyze the mass spectra and
calculate the average of the mass envelope. The procedure for further
data processing was described previously.43,44
iPLA2 Coverage Map of Pepsin Fragmentation and
Deuterium On-Exchange. The recombinant iPLA2 after purification
was confirmed to be active in the mixed-micelle assay. The procedure
of protein digestion by pepsin was previously described.43 Among
them, 153 peptides had a sufficient signal-to-noise ratio for analysis,
which covered 88% of the total protein sequence. From these 110
peptides, 46 different peptides with the least number of overlapped
residues were selected to determine the deuteration level of iPLA2
(Figure 2). Overall, the representative 46 peptides selected account for
71% coverage of the iPLA2.
Deuterium exchange experiments were carried out by incubation of
40 μL of iPLA2 with 80 μL of 95% D2O buffer for six different time
points (10, 30, 100, 300, 1000, and 3000 s) at 23 °C. The sample was
quenched and injected onto the HPLC online digestion system.43−45
The triplicate experiments were carried out with three different
batches of enzyme on different days. The deuteration level increase
over time due to the amide H/D exchange. The exchange results in
various regions were calculated as the ratio of incorporated deuterons
to the maximum deuteration in a particular peptide (Figure 4).
Because of the fast off-exchange rate of N-terminal residues, these
residues are unable to retain any deuterons under the experimental
conditions employed; hence, these residues were not shown in the
results. Some peptides that showed a poor signal-to-noise ratio after
deuteration were also excluded from analysis.
Structural Models and MD Simulation. The Prime protein
structure prediction suite46 was used to build a homology model for
the catalytic domain of iPLA2, using as a template the X-ray structure
of patatin (40% sequence homology), solved at a resolution of 2.2 Å
(PDB code 1OXW).47 The 329 amino acid model for the catalytic
domain was solvated in VMD,48 in a cubic periodic box containing a
physiological concentration of Na+ and Cl− ions of 0.10 mol/L.
Ionizable side chains were kept in their default charge states for pH 7,
and the His residues were kept uncharged. All simulations were
conducted in NAMD 2.949 with the CHARMM27 force field.50 A time
step of 2.0 fs was used in combination with the SHAKE algorithm.51
The temperature was regulated with a Langevin thermostat.52
Figure 2. Pepsin-digested peptide coverage map of GVIA iPLA2. Peptides shown as solid lines were used to depict the deuteration level by use of the
color index in Figure 4.
Figure 3. Inhibition of the activity of human GVIA iPLA2 by PHFK
[XI(50) = 0.0013] tested on mixed micelles.
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Energy minimization was conducted for 25 000 steps with the
protein backbone atoms fixed, followed by two consecutive 20 ns MD
runs in the NPT and NVT ensembles. Subsequently, two production
runs were conducted for 200 ns in the NVT ensemble. The overall
structural stability of the model was indicated by a stable root-mean-
square-deviation (RMSD) for the backbone atom positions during the
simulations. After only ∼3 ns of MD, the potential energy had reached
a plateau and the RMSD of backbone atoms stabilized below 3 Å.
Inspection of the trajectories revealed that the integrity of the
secondary structure was maintained (Figure 1C). In the spirit of the
relaxed complex scheme,53 trajectories were clustered into a reduced
ensemble of 50 representative structures for ligand docking. Empty
pockets inside the protein were monitored by computing the solvent-
accessible surface in VMD. The ligand was docked with Glide
software,54 using the OPLS-2005 force field for its parametrization55
and an inner docking box of length 10 Å.
■ RESULTS AND DISCUSSION
DXMS Characterization of iPLA2−PHFK Interaction.
The significant deuteration changes upon PHFK binding are
located in the catalytic domain of iPLA2 (Figure 5). In
particular, five regions surrounding the active-site dyad, residues
483−493, 516−525, 544−549, 631−655, and 773−778,
showed the most significant decrease of deuteration (Figure
6), while none of the regions showed an increase in H/D
exchange.
Region 483−493 contains the DXMS information from three
peptide fragments: 483−490, 483−493, and 486−493. In the
absence of inhibitor, the deuteration level was observed to
increase, from 10% to 30%, from 10 s to 50 min. The same
experiment repeated in the presence of PHFK led to a
deuteration level below 10% during the whole 50 min time
course. Region 493−498 is located in a stable helix next to the
C-terminus of region 483−493. It showed a very slow H/D
exchange, of only 2%, after 50 min. Region 516−525, which
contains the active-site Ser519, showed a clear decrease in
deuteration upon PHFK binding. The largest decrease in this
region was 18% at 50 min of exchange. Similarly, region 544−
549 showed a significant decrease of deuteration after 16 min of
H/D exchange. Region 631−655 contains fragments 631−650,
631−655, 632−655, and 632−656 from four individual
peptides. Among these regions, the 631−650 fragment seems
to be responsible for most of the changes. Region 773−778
showed a 12% decrease of H/D exchange at the 50 min time
point, and region 710−730 showed 12% and 9% decrease of
exchange after 10 and 30 s, respectively. Regions 404−442 in
the linker region and 238−269 in the ankyrin repeats also
showed greater than 10% decrease in H/D exchange.
Computational Characterization of the iPLA2−PHFK
Interaction. MD simulations showed that iPLA2 residues,
including active-site residues, are flexible (RMS fluctuation =
∼0.6−0.8 Å). An analysis of the solvent-accessible surface
Figure 4. Deuterium exchange of GVIA iPLA2 with and without PHFK inhibitor. Each bar under the primary sequence is divided into rows
corresponding to different time points from 10 s to 50 min (top to bottom). The color coding indicates the percent of H/D exchange during the
given time period.
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during 2 × 200 ns MD simulations was carried out to discover
transient pockets that could potentially accommodate the
PHFK inhibitor. Fifty representative protein structures were
extracted from the simulations. An analysis of the solvent
accessibility surface revealed that several empty pockets were
large enough to accommodate the inhibitor, including an empty
pocket near the active-site Ser519. Ligand docking was
performed on all the pockets and indicated that the best
docking scores were systematically obtained when the box was
centered on the active site, suggesting a very favorable binding
mode.
In Figure 7, the docked iPLA2−PHFK complex is shown.
The inhibitor is found to sit snugly in the active-site with its FK
group stabilized by polar residues, and its alkyl chain and
benzene ring stabilized by nonpolar side-chains (Figure 8).
More specifically, the carbonyl group of PHFK forms favorable
interactions with the amide groups of Gly486 and Gly487. A
“fluorophilic site” is created by Lys489, Asn658, and Lys729,
while the aliphatic carbon chain is stabilized by a narrow
hydrophobic tunnel formed by residues Thr520, Phe549, and
Leu770. The benzene ring forms hydrophobic contacts with
Met544, Val548, Phe549, and Leu560. DXMS experiments
indicate that these residues display decreased H/D exchange in
the presence of the PHFK ligand (Table 1), in agreement with
the proposed binding mode. Such a noncovalent binding model
is in accordance with previous results demonstrating reversible
inhibition of iPLA2 by trifluoromethyl ketones.
56 Various
experimental results demonstrated that the mechanism of
inhibition of iPLA2 by FKs is quite different than that observed
by cPLA2. In the case of iPLA2, the reaction progress curve was
linear and the binding was fast, indicating a reversible inhibition
not involving slow or tight binding.56
Regulation and Flexibility of iPLA2. The complete
structure of iPLA2 includes seven ankyrin repeats, a linker,
and a catalytic domain. The ankyrin repeats are connected to
Figure 5. Effect of PHFK binding on H/D exchange levels in iPLA2 for six time points from 10 s to 50 min. The color coding indicates the
deuteration level changes during the time period.
Figure 6. Regions of H/D exchange most affected by PHFK binding.
The deuteron number is shown for each fragment in the presence
(black squares) and absence (red circles) of inhibitor. The black and
red curves indicate the number of H/D exchanges at six time points
corresponding to 10, 30, 100, 300, 1000, and 3000 s. Color coding of
structure is as shown in Figure 5.
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the catalytic domain through the linker. Whether and how
ankyrin repeats regulate the catalytic activity of iPLA2 remains
unclear. DXMS experiments suggest that inhibitor binding to
iPLA2 decreases the rates of H/D exchange, with most changes
appearing in the loops surrounding the active site in the
catalytic domain. The decrease in H/D exchange in these
regions appears to be fully explained by direct contact with the
inhibitor, blocking access to phospholipid substrates and
reducing solvent accessibility. However, a minor decrease in
H/D exchange was also observed in the linker region and the
ankyrin repeats, indicating that the perturbation caused by
inhibitor can extend to the whole enzyme. Because only one
linker region and one ankyrin region showed a small 10%
decrease of deuteration after 30 min of H/D exchange, overall,
the structure of the ankyrin repeats and the linker is unlikely to
change dramatically, and only minor shifts in the relative
positions between the ankyrin repeats and the catalytic domain
may occur upon ligand binding. One cannot exclude that
phospholipid substrates may have different properties when
compared to the PHFK inhibitor studied here; however, we
Figure 7. Location of PHFK binding to iPLA2 according to ligand docking and DXMS experiments. The color code indicates regions of decreased
H/D exchange upon ligand binding. The membrane penetration domain (loop 695−730) is believed to anchor the protein at the membrane surface
by entering the membrane. The left and right images correspond to the protein viewed from a direction parallel or perpendicular to the membrane
surface.
Figure 8. Characterization of the inhibitor binding pocket in the catalytic domain of iPLA2. Residues within a 5 Å radius of PHFK are shown.
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expect the perturbation caused by ligand binding to remain
localized to the active site in both cases.
The active-site dyad, Ser519 and Asp652, is conserved in
both patatin and iPLA2. Asp652 is believed to accept a
hydrogen from Ser519 during the initial stages of the catalytic
reaction. Interestingly, no hydrogen bond is present between
the two residues in the crystal structure of patatin, which shows
instead a separation of 3.7 Å. Both Ser519 and Asp652 are
strongly affected by PHFK binding. Ser519 is located in the
region 516−525, showing a H/D exchange decrease of 18%,
and Asp652 is in the region 632−655, which shows a decrease
of 11%. MD simulations of the protein−PHFK complex
suggests that the binding of PHFK helps shorten the distance
between Ser519 H and Asp652 O, from 3.7 to 1.6 Å, creating a
hydrogen bond between the two residues. This hydrogen bond
was also observed in MD simulations of the apoprotein, where
it was seen to typically break and re-form within ∼1 ns.
The regulation of active-site accessibility by the surrounding
flexible loops is another interesting possibility. The structure of
the catalytic domain of iPLA2 is similar to the core structure of
cPLA2, which is one of the well-studied PLA2s. Unlike the
buried active sites of cPLA2, iPLA2 has a more exposed catalytic
domain. However, the active-site serine is surrounded by
several flexible loops that could provide some form of
regulation, including residues 485−487 (glycine loop), 517−
520 (catalytic loop), 540−545, 549−560, 631−653, 695−730
(membrane penetration arm), and 761−775. MD simulations
confirmed a high degree of flexibility in the loop regions, in
particular in the membrane penetration arm domains, (loop
695−730), which could play a role similar to the cap structure
of cPLA2. DXMS experiments show that the effect of PHFK
binding propagates to the loop regions, suggesting some degree
of conformational flexibility in the unstructured loops. In
particular, regions 710−722 and 710−730 in the membrane
penetration arm showed a very slight drop of 7% and 12% in
the deuteration level at 10 s of H/D exchange. This domain was
previously found to undergo a dramatic decrease of H/D
exchange upon binding to membranes.43 However, it appears to
be only slightly affected by inhibitor binding, with a small
degree of change relative to residues in direct contact with the
inhibitor. Thus, we do not expect the binding of PHFK to lead
to complete collapse of the membrane penetration arm to cover
the active site, although the loop could still help create some
form of regulation.
■ CONCLUDING REMARKS
Ligands containing a trifluoromethyl or pentafluoroethyl ketone
and a hydrophobic tail have been identified as potent and
selective inhibitors of GVIA iPLA2,
40 encouraging their utility in
developing new pharmaceutical agents. Computer modeling
and DXMS experiments show that the binding of FK ligands
occurs in the active site, with the inhibitors mimicking the
binding of natural substrates. In the natural enzyme, hydro-
phobic interactions with the phospholipid tail are believed to
help increase the binding affinity of the reactant with respect to
the lysophospholipid product. Similarly, in the iPLA2−PHFK
complex, favorable hydrophobic interactions can explain the
high affinity of the inhibitor. In addition, the perfluoroalkyl
headgroup of FK ligands can substitute for the headgroup of
the phospholipids and enter a fluorophilic site, while the
oxyanion hole in the triglycine region is able to stabilize the FK
carbonyl group through strong hydrogen bonds. The abundant
empty space on both sides of the docked PHFK inhibitor
suggests why FK ligands with larger head or tail groups are also
able to bind to iPLA2.
40 Discovery of the binding mode for
PHFK and the available space for further decoration of the
primary inhibitor represents an important first step toward the
rational design of new selective inhibitors. In future work,
chemical alterations of current inhibitors will be pursued, based
on the binding mode and structural model presented here.
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